Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.

MLA

Olson, Daniel J., et al. “Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 39, no. 24, Aug. 2021, pp. 2647–55. EBSCOhost, https://doi.org/10.1200/JCO.21.00079.

APA

Olson, D. J., Eroglu, Z., Brockstein, B., Poklepovic, A. S., Bajaj, M., Babu, S., Hallmeyer, S., Velasco, M., Lutzky, J., Higgs, E., Bao, R., Carll, T. C., Labadie, B., Krausz, T., Zha, Y., Karrison, T., Sondak, V. K., Gajewski, T. F., Khushalani, N. I., & Luke, J. J. (2021). Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(24), 2647–2655. https://doi.org/10.1200/JCO.21.00079

Chicago

Olson, Daniel J, Zeynep Eroglu, Bruce Brockstein, Andrew S Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, et al. 2021. “Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 39 (24): 2647–55. doi:10.1200/JCO.21.00079.